REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
(RESTORE Trial)
Recruiting in Palo Alto (17 mi)
+18 other locations
BR
GA
Overseen byGuilherme Attizzani, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Medtronic Cardiovascular
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Research Team
GF
Gregory Fontana, MD
Principal Investigator
Los Robles Regional Medical Center
BR
Basel Ramlawi
Principal Investigator
Lankenau Heart Institute
GA
Guilherme Attizzani, MD
Principal Investigator
UH, Cleveland Medical Center
Eligibility Criteria
Inclusion Criteria
I need a second TAVR due to valve failure.
Treatment Details
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Medtronic Transcatheter Aortic Valves (TAV) or Edwards Transcatheter Aortic Valves (TAV)Experimental Treatment2 Interventions
Subjects will receive either a Medtronic TAV or Edwards TAV
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medtronic Cardiovascular
Lead Sponsor
Trials
78
Recruited
37,300+
Geoff Martha
Medtronic Cardiovascular
Chief Executive Officer since 2020
Finance degree from Penn State University
Dr. Kendra J. Grubb
Medtronic Cardiovascular
Chief Medical Officer
MD from Emory University